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Abstract
Background. In Italy, national-level immunization polices are included in the National 
Immunization Prevention Plan (PNPV), whose latest edition – 2017-2019 PNPV – was 
finally approved in February 2017. Coverage rates are a key measure of immunization 
system performance; it can inform and support national and regional polices’ implemen-
tation monitoring, as well as measure the impact of interventions aimed at increasing 
vaccine uptake. 
Methods. We collected, analysed and critically interpreted 2000-2016 Italian national 
infant immunization coverage trends, by different vaccine, target population, and by 
Region. Data were provided by the Directorate General for Prevention of the Italian 
Ministry of Health. 
Results. In 2016, none of the mandatory or recommended vaccines reached the 95% na-
tional coverage target set in the PNPV. Weighted average national coverage for currently 
mandatory vaccines (against Polio, Tetanus, Diphtheria, Hepatitis B) and other antigens 
included in the hexavalent vaccine (Pertussis, and Haemophilus influenzae type b) ranged 
between 93.0% for Hepatitis B and 93.7% for Tetanus; it was lower for Measles, Mumps 
and Rubella vaccines (87.2%), pneumococcal (88.4%) and meningococcal C conjugate 
vaccines (80.7%), with a high degree of heterogeneity by Region. Both hexavalent and 
MMR vaccines coverage rates have been decreasing in the last years, respectively from 
2012 (-2.8%) and from 2010 (-3.6%).
Discussion. Further efforts are needed to increase vaccine uptake in Italy, to improve 
data collection and reporting, as well as to fight the growing phenomenon of the vaccine 
hesitancy so that PNPV’s objectives and targets can be met in the near future.
BACKGROUND
In Italy, immunization programs are managed in the 
context of the National Health Service (NHS) which 
provides universal health coverage: the national level 
defines the core benefit package of health services to 
be guaranteed to all citizens (Essential levels of care or 
LEA) and fund them through the National Health Fund; 
Regions are responsible for planning and implementing 
healthcare services [1]. In the field of immunization, the 
Ministry of Health (MoH), in agreement with the State-
Region Conference, issues the Italian National Immuni-
zation Prevention Plan (Piano Nazionale di Prevenzione 
Vaccinale, PNPV), a guidance document for immuniza-
tion polices aimed at harmonizing immunization strate-
gies across the country and which defines vaccines to be 
actively offered free-of-charge to target populations. On 
the basis of this document, each Region adopts its own 
Regional Immunization Plan and schedule. 
Coverage is a key measure of immunization system 
performance [2]; it can support national and regional 
immunization polices’ implementation monitoring, as 
well as inform on the impact of interventions aimed 
at increasing vaccine uptake. In a well-functioning 
health systems coverage data are routinely collected 
by health authorities [3, 4] but rarely shared within 
the scientific community. In 2015 we reported to the 
international scientific community the structure and 
content of the PNPV 2012-2014, we systematically 
reported how the PNPV was transposed into regional 
immunization programs and, most importantly, we an-
alyzed national-level coverage data to assess to which 
extent the 2012-2014 PNPV objectives and coverage 
targets had been met [5]. We concluded that, despite 
being a milestone for prevention in the Italian health 
policy agenda, the 2012-2014 PNPV had only partially 
succeed in reaching its aims, that coverage rates were 
Address for correspondence: Anna Odone, Dipartimento di Medicina e Chirurgia, Università degli Studi di Parma, Via Volturno 39, 43125 Parma, 
Italy. E-mail: anna.odone@unipr.it.
Carlo Signorelli, Anna Odone, Paola Cella et al.
O
r
ig
in
a
l
 a
r
t
ic
l
e
s
 a
n
d
 r
e
v
ie
w
s
232
decreasing and much work was left to be done. In the 
paper we also discussed the barriers to effective imple-
mentation of immunization programmes in Italy that 
would needed to be tackled in the next edition of the 
PNPV. 
Aim of the current study is to report Italian vaccine 
coverage trends over the last 16 years, by different vac-
cines, target populations and selected geographical fac-
tors, as well as to interpret them in the context of Italian 
national immunization polices implemented through-
out the study period.
METHODS 
In this paper we pool, analyse and critically interpret 
national-level infant immunization coverage rates for 
the period 2000-2016. Data were provided by the Di-
rectorate General for Prevention (DGP) of the Italian 
Ministry of Health. 
Infant immunization coverage rates are calculated 
computing number of immunised subjects by resident 
target population, expressed as percentages. The MoH 
has reported, on a year-basis since 2000, 24 months of 
age coverage rates of mandatory and recommended 
infant vaccinations included in the National Immu-
nization Schedule, by Region, as well as by residents-
weighted national average. Since 2013 coverage rates 
are also calculated at 36 months of age, at 5-6 years of 
age (for booster doses) and by single antigen.
Reporting flow of immunization data in Italy
In Italy the reporting flow of immunization data 
mirrors the heterogeneous structure of the different 
Regional Health Services. Regions on a year-basis re-
port to the MoH on absolute numbers of immunised 
subjects (numerators) and target populations (denomi-
nators). Some Regions use the national standard Im-
munization Information Systems (IIS), while others 
have local IISs. In the latter case, Departments of Pre-
vention of Local Health Authorities (LHAs) – which 
implement and manage immunization services at the 
local level – periodically provide Regions with vaccines’ 
programmes monitoring data, including immunisation 
data and adverse events (AEs) reporting. Regions are 
responsible for collecting data from all local health au-
thorities, pooling and sending them to the central level, 
(DGP of the MoH) on a yearly periodicity (deadline 
April of the year after data are referring to), using a 
standardized data collection form. 
The central level is responsible for:
1. defining the reporting system for immunization cov-
erage data in terms of: timing, responsibilities and 
data requirements;
2. collecting from the different Regions, harmonizing 
and pooling coverage rates on a year-basis;
3. analysing data, calculating vaccination coverages and 
interpreting them, carrying out comparisons by dif-
ferent LHAs and regional settings, also on the basis 
of infectious diseases surveillance trends; 
4. disseminating national-level immunization coverage 
rates through the website of the MoH, identifying 
critical issues on where to focus to improve vaccine 
uptake.
Coverage targets
The PNPV sets, for each vaccine included in the 
PNPV National Immunization Schedule, 24 months 
of age coverage targets (for completed vaccines courses 
and for MMR first dose) to be met by Regions. Cov-
erage targets are set taking into account pathogens’ 
specific herd immunity thresholds needed to interrupt 
infectious diseases transmission at the population level. 
The coverage targets defined in the last edition of the 
PNPV (2012-2014 PNPV) [5] and currently applied 
to mandatory and recommended infant immunization 
programmes are set at ≥ 95% for the following vaccines: 
Tetanus, Diphteria, Acellular Pertussis, Hepatitis B, In-
activated Polio, Haemophilus influenzae type b, Measles, 
Mumps, Rubella, Pneumococcal and Meningococcal C. 
Analysis
We carried out descriptive analysis on national-level 
coverage data for all vaccines programmes included in 
the 2012-2014 PNPV’s National Immunization Sched-
ule. All data were provided by the DGP of the Italian 
MoH and compiled in a comprehensive database. Al-
though throughout the study period the MoH has col-
lected coverage rates from Regions by different vaccine 
formulations (i.e Diphtheria, Tetanus and acellular Per-
tussis vaccine – DTaP or Diphtheria and Tetanus vac-
cine + Diphtheria, Tetanus, and acellular Pertussis vac-
cine – DT-DTaP; [6]), we present coverage figures by 
single preventable disease and by single vaccine. Based 
on data availability, we carried out descriptive analysis 
for the national and a regional level. 
Primary outcomes were vaccine coverage rates at 24 
months (for the period 2000-2016) and 36 months (for 
the period 2013-2015) for the following vaccines:
• Inactivated Poliomyelitis, Diphtheria, Tetanus and 
acellular Pertussis; Haemophilus influenzae type b; 
Hepatitis B;
• Measles, Mumps, and Rubella;
• Pneumococcal conjugate;
• Meningococcal C conjugate vaccines;
• Varicella. 
In particular, we report on two sets of analyses: i) we 
present current immunization coverage data, expressed 
as the most updated coverage rates (year 2016) by pre-
ventable disease (cross sectional design analysis), then 
ii) we present immunization coverage trends over time, 
expressed as percentage change in vaccine coverage 
over different time periods. Of note, Pneumococcal 
and Meningococcal C conjugate vaccines coverage is 
only available for the period 2013-2016, as those two 
vaccines were included in the National Immunization 
Schedule to be actively offered free of charge to the tar-
get population starting from year 2012 (2012-2014 edi-
tion of the PNPV). Varicella immunization coverage is 
reported from year 2013 and has been actively offered 
free of charge – as a pilot project – only in eight Regions 
(Apulia, Basilicata, Calabria, Friuli Venezia Giulia, Sar-
dinia, Sicily, Tuscany and Veneto).
RESULTS
National level immunization coverage rates for the 
period 2000-2016 by single antigen are reported in Ta-
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ble 1. At the national level, none of the currently man-
datory (against Polio, Tetanus, Diphtheria, Hepatitis 
B) or recommended vaccines reached the 95% cover-
age target set in the PNPV. In 2016 coverage rates ex-
ceeded 90% for Polio (93.3%), Tetanus (93.7%), Diph-
theria (93.6%), Pertussis (93.6%), Hepatitis B (93.0%) 
and Haemophilus influenzae type b (Hib; 93.1%) vac-
cines; they ranged between 85% and 90% for Measles 
(87.3%), Mumps (87.2%), Rubella (87.2%) and Pneu-
mococcal Conjugate (88.4%) vaccines and was 80.7% 
for Meningococcal C Conjugate vaccine. 
Regional level coverage rates for year 2016 are report-
ed in Table 2. Seven (33%) Regions out of 21 met the 
95% PNPV coverage target for Polio, Tetanus, Diph-
theria and Pertussis vaccines, 6 (28.6%) Regions met 
the 95% PNPV coverage target for Hepatitis B and Hib 
vaccines. Regional vaccine coverages for those vaccines 
ranged from 97% to 85%, with highest rates reported 
in the Basilicata, Molise, Abruzzo, Calabria, Lazio and 
Calabria Regions and lowest in the Veneto, Sicilia and 
Valle d’Aosta Regions and the Autonomous Province of 
Bolzano (Table 2). Only one Region (Basilicata) met the 
95% PNPV coverage target for Pneumococcal Conju-
gate vaccine (regional range: 97%, Basilicata-81%, Au-
tonomous Province of Bolzano). 
None of the Regions met the 95% coverage target 
for Measles, Mumps, Rubella or Men C conjugate vac-
cines, with regional ranges ranging between 93% and 
68% for Measles, Mumps and Rubella vaccines and 
between 91% and 61% for Men C conjugate vaccine 
(Table 2). Measles, Mumps and Rubella coverage was 
highest in the Lombardy and Piemonte Regions, the 
only two Region exceeding 91% coverage, and lowest 
(below 80%) in the Molise Region, together with the 
Autonomous Province of Bolzano.
Looking at trends, national-level 2000-2016 cover-
age rates are reported in Table 1 and Figure 1. With 
regard to mandatory vaccines (Polio, Hepatitis B, Tet-
anus and Diphteria) coverage rates were maintained 
above the 95% coverage target from 2002 to 2013 and 
have been decreasing since then. In particular, manda-
tory vaccines coverage has decreased by, on average, 
2.8% in the last four years (2012-2016; percentage 
decrease being highest for hepatitis B vaccine, -3,1% 
and lowest for Tetanus vaccine, -2.6%). This decreas-
ing trend have been reported in almost all Regions: 
between 2012 and 2016 five Regions (Friuli Venezia 
Giulia, Valle d’ Aosta, Marche, Sicily and the Autono-
mous Province of Bolzano) reported ≥ 4% decrease in 
mandatory vaccines coverage, while only one Region 
(Sardinia) reported a positive figure (+2.5%). Cover-
age trends for all Regions are reported in details in the 
Supplementary Material.
Over the study period, Measles, Mumps and Rubella 
vaccine coverage has never met the 95% coverage targets 
(Figure 1). MMR vaccine coverage has been increasing 
from 2000 to 2010, it was highest in 2010 (90.6%) and 
has drastically decreased since then. In the 2010-2016 
study period, Measles vaccine coverage in Italy decreased 
by 3.6%, with decreasing trends reported in all Regions. 
In 9 (43%) Regions, the percentage decrease was greater 
than 5% and in 3 Regions (Friuli Venezia Giulia, Marche 
and Molise) greater than 9.5% (see supplementary ma-
terial). Of note, measles, mumps and rubella coverage 
rates increased at the national level between 2015 and 
2016 by 2.3%, this increase being greater than 2% in all 
but eight Regions (range: -5% – +4.1%) 
Coverage rates at 36 months of age are available 
since 2013. In Table 3 coverage rates at, respectively, 24 
and 36 months of age are compared for birth cohorts 
2010, 2011, 2012 and 2013. As emerges from the table, 
for birth cohorts 2010, 2011 and 2012, 95% coverage 
targets were met at 36 months of age for mandatory 
vaccines, pertussis and Hib. In particular, the percent-
age of non-vaccinated subjects who got vaccinated at 
36 months of age was highest in the 2012 birth cohort, 
exceeding 11% for all vaccines (Table 3). The high-
est percentages were reported for Measles, Mumps 
and Rubella vaccines for birth cohorts 2010 (23% for 
Measles and 27.8% for Mumps and Rubella), 2012 and 
2013, exceeding 18% for all three vaccines. In the eight 
regions that piloted varicella, universal immunization 
coverage in 2016 ranged between 85.5% in the Veneto 
region and 64.5% in the Calabria Region, with hetero-
geneous regional 2013-2015 trends (see Table 2 and 
Supplementary Material).
Table 1
National level* 24 months of age Infant immunization coverage rates (% per 100 target population), by year 2000-2016
Antigen 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Polio 96.6 95.8 95.9 96.6 96.8 96.5 96.5 96.7 96.3 96.1 96.3 96.1 96.1 95.7 94.7 93.4 93.3
Tetanus 95.3 95.9 96.8 96.6 96.6 96.2 96.6 96.7 96.7 96.2 96.4 96.3 96.2 95.8 94.8 93.6 93.7
Diphtheria 95.3 95.9 96.8 96.6 96.6 96.2 96.6 96.7 96.7 96.2 96.4 96.3 96.2 95.8 94.7 93.4 93.6
Pertussis 87.3 93.3 92.9 95.8 94.0 94.7 96.2 96.5 96.1 96.0 96.2 95.8 96.0 95.7 94.6 93.3 93.6
Hep B 94.1 94.5 95.4 95.4 96.3 95.7 96.3 96.5 96.1 95.8 95.8 96.0 96.0 95.7 94.6 93.2 93.0
Hib 54.7 70.2 83.4 90.4 93.8 94.7 95.5 96.0 95.7 95.6 94.6 95.6 94.8 94.9 94.3 93.0 93.1
Measles 74.1 76.9 80.8 83.9 85.7 87.3 88.3 89.6 90.1 89.9 90.6 90.1 90.0 90.4 86.7 85.3 87.3
Mumps 74.1 76.9 80.8 83.9 85.7 87.3 88.3 89.6 90.1 89.9 90.5 89.9 89.2 90.3 86.7 85.2 87.2
Rubella 74.1 76.9 80.8 83.9 85.7 87.3 88.3 89.6 90.1 89.9 90.5 89.9 89.2 90.3 86.7 85.2 87.2
Men C              77.1 73.9 76.6 80.7
Pneumo              86.9 87.5 88.7 88.4
Hib: Haemophilus influenzae type b; Men C: Meningococcal C Conjugate; Hep B: Hepatitis B; *weighted average. 
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DISCUSSION
We present a comprehensive, reliable and relevant set 
of Italian national-level immunization coverage data, 
focusing on vaccine programmes for infants and chil-
dren over the last sixteen years (2010-2016).
Overall in Italy coverage rates have been decreasing 
since 2012 and are – as for now – still below the targets 
established by the MoH. We report a high degree of 
heterogeneity within the different Italian Regions and 
by vaccine. 
With regard to mandatory immunizations, together 
with the other antigens contained in the hexavalent vac-
cine (i.e Hib and Pertussis) just about one third of Ital-
ian Regions reached the 95% coverage targets in 2016, 
with other Regions reporting coverage rates lower than 
90%. Measles, Mumps and Rubella coverage rates are 
lower, averaging 87% at the national level, with hetero-
geneous regional patterns. Of great importance, both 
hexavalent and MMR vaccines coverage rates have 
been decreasing in the last years, respectively from 
2012 (-2.8%) and from 2010 (-3.6%). Detailed data 
on varicella immunization programmes in selected re-
gions since its introduction are provided by the Inter-
regional Group on Varicella Vaccination (IGVV) [7]. 
Of particular note, four out of the 8 pilot Regions that 
implemented a two-dose schedule Varicella immuniza-
tion have MMR coverage rates higher than the national 
average. Data on Pneumococcal and Meningococcal 
C conjugate vaccines, included in the National Im-
munization Schedule for the first time in 2012, suggest 
that – although far from meeting PNPV targets – both 
vaccines have been well introduced in infant immuniza-
tion schedules in all Regions reaching, respectively, over 
88% and 81% coverage at the national level in 2016. 
The case of the Veneto Region is peculiar: being the 
only Italian Region that in 2007 suspended mandatory 
vaccination [8], after more than seven years it reports 
one of the lowest regional coverage rate for the hexava-
lent vaccine. Such figure is to be interpreted and further 
discussed as it could inform the debate on whether to 
change regional immunization polices. 
Overall, it is worth recalling that factors responsible 
for the reported wide variability of coverage among Re-
gions include: different and heterogeneous immuniza-
tion offer models across LHAs and Regions, varying 
political commitment to support immunization at the 
local and regional level, and differentially distributed 
general population attitudes towards vaccine, by geo-
graphical setting.
Coverage rates at 36 months of age, which are avail-
able starting from year 2013, and which are higher than 
rates at 24 months of age, suggest that a considerable 
share of the population get their children vaccinated 
with delay, a characteristic comprised in the definition 
of vaccine hesitancy [9, 10].
Our study has some limitations. First, data come 
Table 2
National level* 24 months of age Infant immunization coverage rates (% per 100 target population), by Region - year 2016
Region Polio Tetanus Diphtheria Pertussis Hepatitis 
B
Hib Measles Mumps Rubella Varicella Pneumo Men C
Piedmont 95.1 95.4 95.1 95.1 94.7 94.3 91.1 91.1 91.1 91.8 89.3
Aosta Valley 90.9 91.3 90.8 90.8 90.7 90.9 83.4 82.9 83.1 87.4 84.7
Lombardy 92.8 94.4 94.2 94.2 91.9 92.9 93.4 93.3 93.3 85.7 88.2
Aut. Prov.  
of Bolzano
85.1 85.3 85.3 85.2 84.9 84.8 67.5 67.4 67.5 80.5 63.2
Aut. Prov.  
of Trento
93.0 93.3 92.9 92.8 92.6 92.4 87.4 87.3 87.3 89.2 86.0
Veneto 92.0 92.5 92.0 92.0 91.4 91.3 89.2 89.1 89.1 85.5 84.5 90.6
Friuli-Venezia 
Giulia
89.4 89.8 89.3 89.3 88.7 88.7 83.2 83.1 83.2 74.5 81.4 85.4
Liguria 94.3 94.4 94.3 94.3 94.2 93.7 82.2 82.1 82.1 91.8 77.6
Emilia-Romagna 93.3 93.5 93.1 93.1 92.7 92.2 87.5 87.3 87.3 90.6 87.7
Tuscany 94.4 94.6 94.4 94.4 94.1 94.0 89.4 89.3 89.4 75.3 89.0 90.7
Umbria 94.5 94.6 94.5 94.5 94.0 94.3 89.9 89.8 88.4 91.6 89.2
Marche 92.4 92.6 92.3 92.2 92.0 91.8 83.0 83.0 83.0 89.4 80.8
Lazio 96.9 96.8 96.8 96.8 96.7 96.7 87.9 87.9 87.9 93.8 81.1
Abruzzo 97.1 97.1 97.1 97.1 97.0 97.0 87.6 87.6 87.6 89.3 62.6
Molise 97.3 97.3 97.3 97.3 97.3 97.3 73.5 73.5 73.5 91.5 71.7
Campania 92.7 92.7 92.7 92.7 92.7 92.7 83.9 83.9 83.6 82.1 61.0
Apulia 93.3 93.3 93.3 93.3 93.4 93.3 85.9 85.9 85.9 82.4 91.4 78.6
Basilicata 97.4 97.4 97.4 97.4 97.4 97.4 90.6 90.6 90.6 82.6 97.0 88.1
Calabria 95.8 95.8 95.8 95.8 95.8 95.8 86.5 86.5 86.5 64.5 90.0 70.7
Sicily 91.6 91.6 91.6 91.6 91.6 91.6 81.1 81.1 81.1 78.3 88.5 67.2
Sardinia 95.7 95.6 95.6 95.6 95.6 95.6 90.3 90.3 90.3 77.9 94.2 87.9
Italy* 93.3 93.7 93.6 93.6 93.0 93.1 87.3 87.2 87.2 88.4 80.7
Hib: Haemophilus influenzae type b; Men C: Meningococcal C Conjugate; *weighted average.
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from administrative sources whose quality might par-
tially differ by Region. In fact, Regions use slightly dif-
ferent denominators sources to compute coverage rates 
including civil registries, healthcare registries or Italian 
National Institute of Statistics data on residents. As 
progress are being made to harmonize immunization 
information systems and implement electronic vacci-
nation registries in the whole country, data quality will 
improve and regional comparisons will become more 
reliable. Scant data are available on Pneumococcal, and 
meningococcal C vaccines whose coverage rates are 
only reported since 2013 or in the context of ad hoc 
projects [11], nor allow us to distinguish between dif-
ferent available vaccines. With regard to data analysis, 
a limitation is that we kept a descriptive approach. Al-
though we acknowledge that accounting in our analysis 
for ecological-level factors that might impact on vac-
cine uptake over time and in different Regions might 
have provided us with elements useful to understand 
how vaccine coverage can be increased – that was not 
the aim of this study. Last, we did not present vaccine 
preventable diseases’ (VPDs) burden in terms of no-
tifications and hospitalization, nor we speculated on 
VPDs burden prevented through immunization – the 
most important indicators to assess immunization pro-
grammes’ effectiveness – as this would have broadened 
too much the scope of our work. Further studies will 
explore in depth these issues.
CONCLUSION
National immunization coverage targets are only par-
tially met in Italy. Furthermore, Italy, similarly to other Eu-
ropean countries is facing the threatening phenomenon 
of the vaccine hesitancy and has reported in recent years 
alarming decreasing trends in infant vaccine coverage. 
The debate around vaccine uptake and immuniza-
tion policies and practices has recently flourished; if on 
one hand international and national health authorities 
have recently renewed their commitment to promote 
(VPDs) prevention and to strengthen immunization 
programs [12, 13]; on the other hand, recent evidence 
suggests that vaccines are losing public confidence [14]. 
Different and setting-specific determinants have 
been identified to lower vaccine uptake or willingness 
to get vaccinated [9, 14, 15]. In Italy key events in-
cluding: news – later disproved – of vaccine-associated 
deaths [16], court decisions – later reversed – allowing 
financial compensation for vaccines-associated adverse 
events, together with the action of anti-vaccination 
movements have largely contributed to decrease gen-
eral population’s positive attitudes toward vaccines and, 
ultimately, have negatively impacted on vaccine uptake.
In February 2017, the Ministry of Health issued the 
2017-2019 National Immunization Prevention Plan 
[17]; the new Plan introduces evidence-based immu-
nization recommendations to new vaccines and new 
target populations and is considered within the most 
innovative public national immunization plans in Eu-
rope [18, 19]. The new 2017-2019 PNPV [17], was 
approved after a two-year long administrative process 
and political debate, and demonstrates the commit-
ment of the Italian MoH and the entire Government 
to promote immunization polices in Italy [18]. The Ital-
ian scientific community, with a strong partnership of 
four national scientific and professional associations 
(Italian Society of Hygiene, Preventive Medicine and 
Public Health – SItI, Italian Society of Pediatrics – SIP, 
Italian Federation of Family Pediatricians - FIMP, Ital-
ian Federation of General Medicine - FIMMG) has 
greatly contributed to the technical part of the process 
[20, 21]. In line with 2017-2019 PNPV principles and 
taking into consideration the reported decreasing cov-
100%
95%
90%
85%
80%
75%
70%
Hepatitis B
Polio
Tetanus - Diphteria
PNPV 95 target
MMR
Figure 1
National-level* immunization coverage rates (% per 100 target population), over time for selected vaccines 2000-2016
• Hepatitis B, Polio and Tetanus vaccine coverage at 24 months for completed courses (three doses)
• Measles. Mumps, and Rubella vaccine coverage at 24 months, first dose
*weighted average; PNPV: National Immunization Prevention Plan.
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erage trends some Regions have recently approved re-
gional laws making attendance to childcare conditional 
on immunization, while, at the central level, there is 
political will to increase the number of mandatory vac-
cines programmes. As a matter of fact, there is recent 
evidence from California, US supporting the positive 
impact of a mandatory approach to children immuniza-
tion on vaccine uptake [22]. Now, for the new PNPV 
to be effectively implemented and – most importantly 
– for vaccine uptake trends to start increasing again, 
the political commitment and the scientific community 
advocacy action [23] need to be complemented with 
renewed efforts to carry out effective training, infor-
mation and communication interventions to promote 
immunization among healthcare professionals and to 
increase the demand for immunization in the general 
population [24-26]. In particular, the potential offered 
by Information and Communication Technologies and 
“new media” should be leveraged by institutions and 
the public health community to inform and educate the 
general public on the benefits of vaccination [27-32]. 
Immunization coverage data are of crucial importance 
to inform the planning, and implementation of those 
actions, as well as to assess their impact. As vaccine 
coverage for mandatory and recommended vaccines is 
included in the set of the health indicators identified 
to monitor LEAs provision at the national level, we 
urge strengthened efforts will be devoted in the years to 
come to its rigorous collection through IIS implementa-
tion, to its analysis, its interpretation and dissemination 
at the national and international level.
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